Recursion (RXRX) Q3 2026 Earnings Call Transcript

Recursion reported Q3 revenue of $18.6 million, up from $5.2 million a year earlier, and a net loss of $119 million versus $162.3 million; pro forma cash was approximately $748.7 million, with runway extended into 2029 after an oversubscribed October offering that generated $200 million gross. In the TUPELO study, 13 of 15 evaluable patients had reduced polyp burden after 12 weeks of REC-4881, while REC-1245 showed disease control in 11 of 12 evaluable patients at doses of 45 mg or higher, including two confirmed partial responses in endometrial cancer. Management guided to cash operating expenses below $375 million in 2026 and $360 million in 2027; both drug programs remain investigational, and 65 mg REC-1245 exceeded the maximum tolerated dose, with dose-limiting toxicities in three of four patients.

Analysis

The investable signal is improved survival time and better capital allocation—not validation of an AI platform as a scalable business. Partner milestones and an optioned Sanofi candidate provide external checks on Recursion Pharmaceuticals’ discovery work, while Sanofi taking development forward may cap Recursion’s future cash burden. But neither milestone receipts nor partner interest establish clinical success; the economics matter only if programs advance toward meaningful royalties or additional milestones. That makes the partner news strategically positive but unlikely, on its own, to move Sanofi or Roche Holding’s consolidated earnings outlook.

For Recursion, the near-term balance-sheet overhang is reduced, but the most consequential catalysts are distant: FDA alignment and a potential registrational study for REC-4881, then REC-1245 expansion data, both pointing to 2027. The FAP results are encouraging but based on a small evaluable cohort and polyp burden is not itself proof of fewer surgeries, cancers, or other outcomes regulators may require. REC-1245’s responses are also early and heterogeneous; the 65 mg toxicity experience narrows the practical dose window. The key second-order risk is that cost discipline preserves runway but may also signal the need to ration a broad pipeline around only a few shots on goal.

Contrarian read: durability off treatment could ultimately improve tolerability and adherence in chronic FAP, but investors may be capitalizing that possibility before dose schedule, endpoint, and registration design are settled. Treat the call as a de-risking update, not a near-term inflection in commercial value.

Key Decisions for Investors

• Do not chase an event-driven move in Recursion Pharmaceuticals solely on the small-cohort readouts or management’s platform claims. Consider only a small, staged exposure if the stock sells off without deterioration in clinical data; avoid sizing it as a commercial-stage biotech.
• For a 1–3 month watch, track FDA feedback on REC-4881’s registrational design, the endpoint and control strategy, and any updated safety or durability data. A credible path to a registration-relevant endpoint would strengthen the thesis; a requirement for a materially larger or longer study would weaken it and raise funding risk.
• Treat REC-1245 as an option on early activity, not a validated oncology franchise. Monitor expansion-cohort enrollment and the expected 2H 2027 readout for response rate, duration of response, and tolerability at the selected dose; falling responses or dose-limiting toxicity at that dose would falsify the early signal.
• No trade in Sanofi or Roche Holding on these updates alone: the collaboration evidence is strategically favorable, but the disclosed milestone and option activity do not establish a material change to either partner’s earnings. Reassess only if partner programs generate larger payments, enter clinical testing, or change the partners’ guidance.